TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04531969

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spa therapy and conventional physical therapy
Description: HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spa therapy and conventional physical therapy
Description: HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day.
Study: NCT02207764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
Study: NCT02582307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Analgesics, Non-Narcotic
Description: Oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide, Analgesics, Non-Narcotic
Description: Oral single dose
Study: NCT00826241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Starting dose 1250 mg daily by mouth.
Study: NCT01640041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio-frequency Microstiumulator
Description: All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
Study: NCT04106063

Intervention type: OTHER
Intervention: KID SSQ12 questionnaire
Description: During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
Study: NCT01582464

Intervention type: BEHAVIORAL
Intervention: Social Marketing for protective headgear
Description: Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), \& a demographic \& functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes.
Study: NCT03211130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE™
Description: During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-Control
Description: An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
Study: NCT03710785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cervical spine extension exercise
Description: cervical spine extension exercise for 4 weeks
Study: NCT01283581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delafloxacin
Description: 300mg IV every 12 hours for 5-14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600mg IV every 12 hours for 5-14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
Study: NCT03415464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: neuromuscular training
Study: NCT04077203

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Biofeedback / No biofeedback
Description: Biofeedback / No biofeedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback / No biofeedback
Description: Biofeedback / No biofeedback
Study: NCT00933335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Tositumomab and Iodine I 131 Tositumomab
Study: NCT02432677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.

Intervention type: DEVICE
Group type: OTHER
Intervention: Active tDCS
Description: The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham tDCS
Description: The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham tDCS
Description: The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
Study: NCT03720080

Intervention type: DEVICE
Intervention: OpenAPS
Description: A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
Study: NCT00943033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
Study: NCT03841838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy drink
Description: Two 12 oz bottles of commercially available energy drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
Study: NCT00806871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 40 mg
Description: Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 80 mg
Description: Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline
Study: NCT02894008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChAd63-KH
Description: ChAd63-KH in adults and adolescents with persistent PKDL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChAd63-KH
Description: ChAd63-KH in adults and adolescents with persistent PKDL.
Study: NCT03402048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study: NCT02050542

Intervention type: PROCEDURE
Group type: OTHER
Intervention: systematic biopsies
Description: 90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate

Intervention type: PROCEDURE
Group type: OTHER
Intervention: systematic biopsies
Description: 90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Targeted biopsies guided by a fusion of MRI and ultrasound- images
Description: Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Targeted biopsies guided by a fusion of MRI and ultrasound- images
Description: Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
Study: NCT01744912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab is a novel monoclonal antibody targeting CD20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
Study: NCT03268148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LaserPen
Description: low level laser is used before heel-lancing for newborn screening
Study: NCT00504582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant
Description: Tisseel applied externally to the dissected axillary area.
Study: NCT01196039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study: NCT01593462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRE (magnetic resonance enterography)
Description: The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)
Description: The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Questionnaires
Description: The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete.
Study: NCT01780532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging (PAI)
Description: Standard of Care
Study: NCT02416934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1; Dexamethasone
Description: Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment 0; Saline placebo
Description: Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
Study: NCT03007524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Rosuvastatin
Description: 20mg/d qN, at least 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose Rosuvastatin
Description: 10mg/d qN, at least 6 months
Study: NCT02750878

Intervention type: OTHER
Group type: OTHER
Intervention: Informational Handout
Study: NCT01528735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA
Description: one fix dose
Study: NCT01233219

Intervention type: DRUG
Intervention: morphine chlorhydrate
Description: The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h).

Intervention type: DRUG
Intervention: morphine chlorhydrate
Description: The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h).
Study: NCT00984659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol combination product
Description: Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 50mcg DISKUS twice a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo DISKUS twice a day for 8 weeks
Study: NCT04483362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex physical activity intervention
Description: Structured weekly sessions with a Physiotherapist over an 8 week period, including:~* Evaluation of current levels of physical activity and physical function - including discussion of results~* Education regarding the importance of physical activity~* Supervised physical activity session with a physiotherapist~* Structured weekly sessions applying behavioural change techniques which aim to increase participation in physical activity. Sessions include: provision of activity monitor (Fitbit Inspire), goal setting, monitoring, collaborative problem solving and action plan implementation. Intervention includes additional time allowance of 1 hour per week to assist in implementing action plan items
Study: NCT03418662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoRings device
Description: Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
Study: NCT02831491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV
Study: NCT04489524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized counselor-led MI sessions
Description: Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general health education session
Description: four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NRT
Description: nicotine replacement therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRT
Description: nicotine replacement therapy
Study: NCT01528735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon
Description: per package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: per weight BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: per weight BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA
Description: one fix dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA
Description: high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA
Description: low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon
Description: per package insert
Study: NCT02962180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabrasion with dermaroller
Description: o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
Study: NCT03012451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advancing Adolescents
Description: The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities.
Study: NCT02228486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Exposure Therapy
Description: 5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue Exposure Therapy
Description: 5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)